Merkel Cell Polyomavirus Co-Infection in HIV/AIDS Individuals: Clinical Diagnosis, Consequences and Treatments
- PMID: 40005510
- PMCID: PMC11858345
- DOI: 10.3390/pathogens14020134
Merkel Cell Polyomavirus Co-Infection in HIV/AIDS Individuals: Clinical Diagnosis, Consequences and Treatments
Abstract
Merkel cell polyomavirus (MCV) was named for its role as the causative agent of Merkel cell carcinoma (MCC), which is MCV positive in approximately 80% of cases. MCV is classified as a Group 2A carcinogen, which promotes carcinogenesis by integrating T-antigen into the cell genome. The prevalence of anti-MCV antibodies in the general population can be as high as 90%. MCV typically promotes cancer by integrating T-antigen genes into the host cell genome, and 80% of MCC cases are attributed to MCV activation. In immunocompetent individuals, MCV usually remains latent after infection. However, the incidence of MCC increases significantly in immunocompromised or immunodeficient patients, such as those who have undergone organ transplantation, have chronic lymphocytic leukemia, or are living with human immunodeficiency virus (HIV) infection. Acquired immunodeficiency is a particular feature of people living with HIV. Currently, research on HIV/AIDS patients with MCV infection, clinical outcomes, and treatments is quite limited. This paper reviews previous research and systematically examines the relationship between HIV/AIDS and MCV-associated diseases, with the aim of providing valuable information for the prevention, diagnosis, and treatment of MCV in vulnerable populations.
Keywords: HIV/AIDS; Merkel cell carcinoma; Merkel cell polyomavirus; activation.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Prospective study of Merkel cell polyomavirus and risk of Merkel cell carcinoma.Int J Cancer. 2014 Feb 15;134(4):844-8. doi: 10.1002/ijc.28419. Epub 2013 Aug 29. Int J Cancer. 2014. PMID: 23922031
-
Bcl-2 expression indicates better prognosis of Merkel cell carcinoma regardless of the presence of Merkel cell polyomavirus.Virchows Arch. 2012 Nov;461(5):553-9. doi: 10.1007/s00428-012-1310-3. Epub 2012 Sep 14. Virchows Arch. 2012. PMID: 22976527
-
A review of Merkel cell carcinoma.JAAPA. 2023 Nov 1;36(11):11-16. doi: 10.1097/01.JAA.0000979460.69305.b7. JAAPA. 2023. PMID: 37820270 Review.
-
Merkel cell carcinoma: recent insights and new treatment options.Curr Opin Oncol. 2012 Mar;24(2):141-9. doi: 10.1097/CCO.0b013e32834fc9fe. Curr Opin Oncol. 2012. PMID: 22234254 Review.
-
Merkel cell polyomavirus and Merkel cell carcinoma.Philos Trans R Soc Lond B Biol Sci. 2017 Oct 19;372(1732):20160276. doi: 10.1098/rstb.2016.0276. Philos Trans R Soc Lond B Biol Sci. 2017. PMID: 28893943 Free PMC article. Review.
Cited by
-
Pleural mesothelioma patients and ex-exposed asbestos workers are immunologically poor responders to oncogenic Merkel cell polyomavirus.Transl Lung Cancer Res. 2025 Jul 31;14(7):2611-2625. doi: 10.21037/tlcr-2025-198. Epub 2025 Jul 28. Transl Lung Cancer Res. 2025. PMID: 40799442 Free PMC article.
References
-
- Goldstein R.H., DeCaprio J.A. HIV/AIDS-Associated Viral Oncogenesis. Volume 177. Springer; Cham, Switzerland: 2019. Merkel Cell Carcinoma in the HIV-1/AIDS Patient; pp. 211–229. Cancer Treatment and Research. - DOI
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical